dimethyl fumarate tevapharm gastroresistentne kõvakapsel
teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 100tk; 120mg 14tk
dimethyl fumarate tevapharm gastroresistentne kõvakapsel
teva gmbh - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 168tk
dimtelzo gastroresistentne kõvakapsel
sandoz pharmaceuticals d.d. - dimetüülfumaraat - gastroresistentne kõvakapsel - 120mg 14tk
dimtelzo gastroresistentne kõvakapsel
sandoz pharmaceuticals d.d. - dimetüülfumaraat - gastroresistentne kõvakapsel - 240mg 196tk; 240mg 56tk; 240mg 100tk; 240mg 168tk
libmeldy
orchard therapeutics (netherlands) bv - atidarsagene autotemcel - leukodystrophy, metachromatic - muud närvisüsteemi ravimid - libmeldy is indicated for the treatment of metachromatic leukodystrophy (mld) characterized by biallelic mutations in the arysulfatase a (arsa) gene leading to a reduction of the arsa enzymatic activity:in children with late infantile or early juvenile forms, without clinical manifestations of the disease,in children with the early juvenile form, with early clinical manifestations of the disease, who still have the ability to walk independently and before the onset of cognitive decline.
soliris
alexion europe sas - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - soliris on näidatud täiskasvanute ja laste raviks:paroxysmal öise haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5. ebatüüpiline hemolüütilis-ureemilise sündroomi (ahus). soliris on näidustatud täiskasvanute raviks:tulekindlad generaliseerunud myasthenia gravis (gmg) patsientidel, kes on anti-atsetüülkoliin retseptori (achr) antikeha-positiivsete (vt lõik 5. neuromyelitis optica spectrum disorder (nmosd) patsientidel, kes on anti-aquaporin-4 (aqp4) antikeha-positiivsete koos relapsing haiguse kulg.
ultomiris
alexion europe sas - ravulizumab - hemoglobinuuria, paroksüsmaalne - selektiivsed immunosupressandid - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.
epysqli
samsung bioepis nl b.v. - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.
bekemv
amgen technology (ireland) uc - eculizumab - hemoglobinuuria, paroksüsmaalne - immunosupressandid - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). tõendeid kliinilise kasu on näidanud patsientidel haemolysis kliiniliste sümptomite(s) soovituslik kõrge haiguse aktiivsusega, sõltumata sellest, vereülekande ajalugu (vt lõik 5.
minjuvi
incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastilised ained - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).